Treatment landscape of triple-negative breast cancer—expanded options, evolving needs
G Bianchini, C De Angelis, L Licata… - Nature reviews Clinical …, 2022 - nature.com
Tumour heterogeneity and a long-standing paucity of effective therapies other than
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
G Morad, BA Helmink, P Sharma, JA Wargo - Cell, 2021 - cell.com
Unprecedented advances have been made in cancer treatment with the use of immune
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and …
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and …
[HTML][HTML] Conserved pan-cancer microenvironment subtypes predict response to immunotherapy
The clinical use of molecular targeted therapy is rapidly evolving but has primarily focused
on genomic alterations. Transcriptomic analysis offers an opportunity to dissect the …
on genomic alterations. Transcriptomic analysis offers an opportunity to dissect the …
The challenges of tumor mutational burden as an immunotherapy biomarker
DL Jardim, A Goodman, D de Melo Gagliato… - Cancer cell, 2021 - cell.com
Tumor mutational burden (TMB) reflects cancer mutation quantity. Mutations are processed
to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T …
to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T …
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
D Bruni, HK Angell, J Galon - Nature Reviews Cancer, 2020 - nature.com
Abstract The international American Joint Committee on Cancer/Union for International
Cancer Control (AJCC/UICC) tumour-node-metastasis (TNM) staging system provides the …
Cancer Control (AJCC/UICC) tumour-node-metastasis (TNM) staging system provides the …
A decade of immune-checkpoint inhibitors in cancer therapy
C Robert - Nature communications, 2020 - nature.com
Immunotherapy using immune-checkpoint modulators revolutionizes the oncology field far
beyond their remarkable clinical efficacy in some patients. It creates radical changes in the …
beyond their remarkable clinical efficacy in some patients. It creates radical changes in the …
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
M Chalabi, LF Fanchi, KK Dijkstra, JG Van den Berg… - Nature medicine, 2020 - nature.com
Abstract PD-1 plus CTLA-4 blockade is highly effective in advanced-stage, mismatch repair
(MMR)-deficient (dMMR) colorectal cancers, yet not in MMR-proficient (pMMR) tumors. We …
(MMR)-deficient (dMMR) colorectal cancers, yet not in MMR-proficient (pMMR) tumors. We …
Tumor mutational burden as a predictor of immunotherapy response: is more always better?
Immune checkpoint inhibitors, including antibodies that block programmed cell death protein-
1 (PD-1) and PD-L1, have transformed the management of many cancers. However, the …
1 (PD-1) and PD-L1, have transformed the management of many cancers. However, the …
Non-small-cell lung cancer
Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is
responsible for the majority of cancer-related deaths worldwide. The management of …
responsible for the majority of cancer-related deaths worldwide. The management of …
Enhancing anti-tumour efficacy with immunotherapy combinations
Several tumour types are responsive to immunotherapy, as shown by regulatory approvals
for immune checkpoint inhibitors. However, many patients either do not respond or do not …
for immune checkpoint inhibitors. However, many patients either do not respond or do not …